Trial Profile
An Open-Label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Belinostat (Primary) ; Carboplatin; Paclitaxel
- Indications Cancer; Carcinoma; Solid tumours
- Focus Therapeutic Use
- Sponsors TopoTarget; Valerio Therapeutics
- 28 Aug 2012 Results will be presented at major oncology meetings in 2013, according to a TopoTarget media release.
- 28 Aug 2012 Additional analyses of time to treatment failure were reported in a TopoTarget media release.
- 29 Jun 2012 Top-line safety and efficacy data were published, according to a TopoTarget media release.